2025
Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments
Travers S, Alexandre J, Baldassarre L, Salem J, Mirabel M. Diagnosis of cancer therapy-related cardiovascular toxicities: A multimodality integrative approach and future developments. Archives Of Cardiovascular Diseases 2025, 118: 185-198. PMID: 39947997, DOI: 10.1016/j.acvd.2024.12.012.Peer-Reviewed Original ResearchConceptsCardio-oncologyCardiovascular toxicityCardiovascular imagingMultimodality cardiovascular imagingCancer risk factorsIncrease diagnostic accuracyPrognostic stratificationNatriuretic peptideSerum biomarkersTherapy schemesDiagnostic accuracyCancer therapyRhythm disordersRisk factorsCardiovascular diseaseBiomarkersMultimodal integrated approachCancerOmics approachesToxicityRhythmTherapyTroponinSerumDiagnosis
2022
Advances in Multimodality Imaging in Cardio-Oncology JACC State-of-the-Art Review
Baldassarre LA, Ganatra S, Lopez-Mattei J, Yang EH, Zaha VG, Wong TC, Ayoub C, DeCara JM, Dent S, Deswal A, Ghosh AK, Henry M, Khemka A, Leja M, Rudski L, Villarraga HR, Liu JE, Barac A, Scherrer-Crosbie M, Councils A. Advances in Multimodality Imaging in Cardio-Oncology JACC State-of-the-Art Review. Journal Of The American College Of Cardiology 2022, 80: 1560-1578. PMID: 36229093, DOI: 10.1016/j.jacc.2022.08.743.Peer-Reviewed Original ResearchConceptsCardio-oncology patientsAdverse cardiovascular effectsLong-term survivorsPopulation of patientsCardiovascular complicationsPregnant patientsCardiovascular effectsCardiac massAntineoplastic therapyJACC StateVascular toxicityPatientsMultimodality imagingCancerImagingNumerous advancesReviewComplicationsAtherosclerosisTherapyPopulationDiseaseSurvivorsDiagnosis
2021
Cardiac Magnetic Resonance in Cardio-Oncology Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization
O’Quinn R, Ferrari VA, Daly R, Hundley G, Baldassarre LA, Han Y, Barac A, Arnold A. Cardiac Magnetic Resonance in Cardio-Oncology Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization. JACC CardioOncology 2021, 3: 191-200. PMID: 34396324, PMCID: PMC8352183, DOI: 10.1016/j.jaccao.2021.04.011.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply